Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial
Diabetes Care · 2024
DOI: 10.2337/dc23-0749 ↗Kurz gefasst
Pragmatische Studie in der Zeitschrift Diabetes Care, 2024. Verfasst von Dennis I Narcisse und 21 weiteren Autor:innen. Beteiligte Einrichtung: Duke University Medical Center, Durham, NC. Hauptthemen laut MEDLINE: Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Myocardial Infarction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, Patient-Centered Outcomes Research Institute.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE Patients with diabetes mellitus (DM) and concomitant atherosclerotic cardiovascular disease (ASCVD) must be on the most effective dose of aspirin to mitigate risk of future adverse cardiovascular events. RESEARCH DESIGN AND METHODS ADAPTABLE, an open-label, pragmatic study, randomized patients with stable, chronic ASCVD to 81 mg or 325 mg of daily aspirin. The effects of aspirin dosing was assessed on the primary effectiveness outcome, a composite of all-cause death, hospitalization for myocardial infarction, or hospitalization for stroke, and the primary safety outcome of hospitalization for major bleeding. In this prespecified analysis, we used Cox proportional hazards models to compare aspirin dosing in patients with and without DM for the primary effectiveness and safety outcome. RESULTS Of 15,076 patients, 5,676 (39%) had DM of whom 2,820 (49.7%) were assigned to 81 mg aspirin and 2,856 (50.3%) to 325 mg aspirin. Patients with versus without DM had higher rates of the composite cardiovascular outcome (9.6% vs. 5.9%; P < 0.001) and bleeding events (0.78% vs. 0.50%; P < 0.001). When comparing 81 mg vs. 325 mg of aspirin, patients with DM had no difference in the primary effectiveness outcome (9.3% vs. 10.0%; hazard ratio [HR] 0.98 [95% CI 0.83–1.16]; P = 0.265) or safety outcome (0.87% vs. 0.69%; subdistribution HR 1.25 [95% CI 0.72–2.16]; P = 0.772). CONCLUSIONS This study confirms the inherently higher risk of patients with DM irrespective of aspirin dosing. Our findings suggest that a higher dose of aspirin yields no added clinical benefit, even in a more vulnerable population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Duke University Medical Center, Durham, NC.
- Duke Clinical Research Institute, Duke University, Durham, NC.
- Vanderbilt University Medical Center, Nashville, TN.
- University of Queensland-Ochsner Clinical School, New Orleans, LA.
- University of Kansas Medical Center, Kansas City, KS.
- University of Florida, Gainesville, FL.
ORCID-Profile: Dennis I Narcisse, W Schuyler Jones
Förderung
- NHLBI NIH HHS
- Patient-Centered Outcomes Research Institute
Zitieren
APA
Narcisse, D. I., Kim, H., Wruck, L. M., Stebbins, A. L., Muñoz, D., Kripalani, S., Effron, M. B., Gupta, K., Anderson, R. D., Jain, S. K., Girotra, S., Whittle, J., Benziger, C. P., Farrehi, P., Zhou, L., Polonsky, T. S., Ahmad, F. S., Roe, M. T., Rothman, R. L., …, & Jones, W. S. (2024). Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial. Diabetes Care. https://doi.org/10.2337/dc23-0749
Vancouver
Narcisse DI, Kim H, Wruck LM, Stebbins AL, Muñoz D, Kripalani S, et al. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial. Diabetes Care. 2024. doi:10.2337/dc23-0749
BibTeX
@article{Narcisse2024,
author = {Narcisse, Dennis I and Kim, Hwasoon and Wruck, Lisa M and Stebbins, Amanda L and Muñoz, Daniel and Kripalani, Sunil and Effron, Mark B and Gupta, Kamal and Anderson, R David and Jain, Sandeep K and Girotra, Saket and Whittle, Jeff and Benziger, Catherine P and Farrehi, Peter and Zhou, Li and Polonsky, Tamar S and Ahmad, Faraz S and Roe, Matthew T and Rothman, Russell L and Harrington, Robert A and Hernandez, Adrian F and Jones, W Schuyler},
title = {Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial},
journal = {Diabetes Care},
year = {2024},
doi = {10.2337/dc23-0749}
}
EUVIMED